中(zhong)國(guo)抗體(ti)(ti)制(zhi)藥有限公(gong)司(「中(zhong)國(guo)抗體(ti)(ti)」或「公(gong)司」,股(gu)份代號:3681.HK)專注(zhu)于研(yan)究、發展(zhan)、制(zhi)造及(ji)商(shang)業化免(mian)疫性疾病療法,主要研(yan)制(zhi)以單(dan)(dan)克隆(long)抗體(ti)(ti)為(wei)(wei)基礎的生物(wu)藥。公(gong)司注(zhu)重科技研(yan)發,其旗(qi)艦(jian)產品(pin)SM03為(wei)(wei)全球首(shou)項用以治療類風(feng)濕(shi)(shi)關(guan)(guan)節炎(yan)的潛(qian)在抗CD22單(dan)(dan)抗,已在中(zhong)國(guo)進(jin)入類風(feng)濕(shi)(shi)關(guan)(guan)節炎(yan)三期(qi)臨床(chuang)試驗,并被列(lie)入國(guo)家十三五重大新(xin)藥創制(zhi)專項重大項目。此外還有多個(ge)同類靶點首(shou)創(First-in-target)及(ji)同類首(shou)創(First-in-class)潛(qian)在在研(yan)藥物(wu),部分已處于臨床(chuang)階段,適應癥覆蓋類風(feng)濕(shi)(shi)性關(guan)(guan)節炎(yan)、系統性紅(hong)斑狼瘡、非霍奇金(jin)氏淋巴瘤、哮(xiao)喘等具(ju)有重大未滿足臨床(chuang)需求的疾病。